Search
A pioneering study led by Shi Jun, a prominent physician at the Hematology Department of the Chinese Academy of Medical Sciences, has revealed a groundbreaking approach to treating recurrent autoimmune hemolytic anemia (AIHA). The team successfully treated two AIHA patients who had failed multiple therapeutic avenues and experienced relapse following autologous CD19 CAR T-cell therapy. The novel rescue therapy employed CM336, a bispecific T-cell engager specifically targeting BCMA and independently developed by Canova. The results demonstrated that this treatment markedly alleviated the patients' hemolytic symptoms, induced treatment-free remission, and was associated with minimal adverse effects. This discovery offers a promising new therapeutic strategy for individuals with autoimmune diseases.
-
C114 Communication Network -
Communication Home
